Out of the total 250 MW of SECI 1 at Dayapar, Gujarat, the company had successfully commissioned 200 MW in June and July, 2019. Further, SECI has also granted permission to the company to commission the balance 50 MW Project, which is already under execution.

On 25th November,overall volumes in futures & options currently stand at 1.08 crore contracts with a turnover of Rs. 7,66,847.28 crore.

The last week turned out to be a lackluster one. Although the Indian stock markets closed with marginal gains, the Nifty 50 index could not sustain above 12,000 levels. For the last three weeks, the index is forming indecisive candles and this candle formation, near the lifetime high levels, is creating confusion among traders. The early indication from the SGX Nifty suggests that the Indian markets are likely to kick-off the new week on a positive note as cues from Asian peers are optimistic.

If the Nifty closes below the 11,800 mark, it will have a downside implication of about more than 200 points. Whereas, on the upside, the index needs to penetrate above the 12,040 mark convincingly to reignite the uber strength of the bulls. Stocks in news: Jubilant Life Sciences, Unichem Laboratories, Ashoka Buildcon, Power Grid, Inox Wind, IDBI Bank.

New Fund Offers (NFOs) that are open for subscription.

Sundaram Mutual has launched a fund of fund scheme that will invest as a feeder fund into the Sundaram Global Brand Fund. Read on to find how to use this fund. 

Zydus Cadila has received final approval from THE USFDA to markets lsosorbide Dinitrate Tablets USP (US RLD - Isordil Tablet), in the strengths of 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg, and also for Desonide Cream (US RLD - Desonide Cream), 0.05%.

Indian equity benchmarks traded weakly throughout the day on Friday and ended the session on a pessimistic note, led by a decline in IT stocks.

Lupin has launched 'Adhero', which is the first-of-its-kind, connected smart device in India to track usage pattern of metered dose inhaler (MDI) by patients. The pharma major also announced the rollout of Hydrocortisone Valerate Cream USP, 0.2%, which is for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.

Dr. Reddy's has launched Doxercalciferol Injection, 4 mcg/2 ml (2 mcg/ml) multiple-dose vials, a therapeutic generic equivalent of Hectorol (doxercalciferol) Injection 4 mcg/2 ml (2 mcg/ml) multiple-dose vials, which has been approved by the U.S. Food and Drug Administration (USFDA).